** Shares of hormonal disease-focused drug developer Crinetics CRNX.O rise 1.6% to $37.1 in premarket after TD Cowen starts coverage with a "buy" rating
** TD Cowen forecasts sales of $4 billion for co's experimental lead drugs by 2035
** Brokerage says market potential of co's once-daily pill paltusotine could be substantial, given similar drugs from Novartis NOVN.S and Ipsen IPN.PA collectively brought in $2.5 billion of sales in 2023
** Co is testing paltusotine to treat acromegaly, a condition in which excess growth hormone is produced, as well as carcinoid syndrome that causes symptoms from rare tumors
** CRNX is testing another drug, atumelnant, for a rare genetic disorder called congenital adrenal hyperplasia $(CAH)$ and Cushing's syndrome, a hormonal disorder
** "The company's success partly relies on its ability to obtain and maintain patent protection in the US and other countries for its product candidates," brokerage says
** Stock rose 44% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。